Notice of Results and Appointment of Joint Broker

Circassia Pharmaceuticals plc

Notice of Interim Results and Appointment of Joint Broker

Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR) announces it will publish its interim results for the six months ended 30 June 2019 on Thursday 26 September 2019. A presentation for analysts will take place at 9.30am on the day and a webcast of the presentation will be available on the Company's website.

Circassia also announces the appointment of finnCap Ltd as joint broker with immediate effect.

Contacts

Circassia

Steve Harris, Chief Executive Officer Tel: +44 (0) 1865 405 560

Julien Cotta, Chief Financial Officer

Rob Budge, Corporate Communications

Peel Hunt (Nominated Adviser and Joint Broker)

James Steel / Dr Christopher Golden Tel: +44 (0) 20 7418 8900

finnCap (Joint Broker)

Geoff Nash / Alice Lane Tel: +44 (0) 20 7220 0500

Numis Securities (Joint Broker)

James Black / Freddie Barnfield Tel: +44 (0) 20 7260 1000

FTI Consulting

Simon Conway / Ciara Martin Tel: +44 (0) 20 3727 1000

About Circassia

Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. The Company sells its market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom, China and Germany, and in a wide range of other countries through its network of partners. In the United States, Circassia has a commercial collaboration with AstraZeneca in which it has the commercial rights to chronic obstructive pulmonary disease (COPD) treatments Tudorza® and Duaklir®. Circassia also has the US and Chinese commercial rights to the late-stage ventilator-compatible nitric oxide product AirNOvent. For more information please visit www.circassia.com.